

Proteome characterization in various biological fluids of *Trypanosoma brucei gambiense*-infected subjects

Julien Bonnet, Camille Garcia, Thibaut Léger, Marie-Pauline Couquet,
Philippe Vignoles, Geddeo Vatunga, Joseph Ndung'U, Clotilde Boudot, Sylvie
Bisser, Bertrand Courtioux

► **To cite this version:**

Julien Bonnet, Camille Garcia, Thibaut Léger, Marie-Pauline Couquet, Philippe Vignoles, et al.. Proteome characterization in various biological fluids of *Trypanosoma brucei gambiense*-infected subjects. Journal of Proteomics, Elsevier, 2018, 10.1016/j.jprot.2018.11.005 . hal-01936184

HAL Id: hal-01936184

<https://hal-unilim.archives-ouvertes.fr/hal-01936184>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



1 Proteome characterization in various biological fluids of *Trypanosoma*
2 *brucei gambiense*-infected subjects

3
4 Julien Bonnet^{1*}, Camille Garcia², Thibaut Leger², Marie-Pauline Couquet¹, Philippe Vignoles¹,
5 Vatunga Geddeao³, Joseph Ndung'u⁴, Clotilde Boudot¹, Sylvie Bisser^{1,5}, Bertrand Courtioux¹.

6
7 **1** Institute of Neuroepidemiology and Tropical Neurology, School of Medicine, CNRS FR 3503
8 GEIST, University of Limoges, INSERM UMR 1094 Tropical Neuroepidemiology, Limoges,
9 France.

10 **2** Jacques Monod Institute, Proteomics Facility, University Paris Diderot Sorbonne Paris Cité,
11 Paris, France.

12 **3** Instituto de Combate e controlo das Tripanossomias (ICCT), Luanda, Angola.

13 **4** Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.

14 **5** Pasteur Institute in French Guiana, 23 Boulevard Pasteur, 973006 Cayenne Cedex, French
15 Guiana.

16 Email: julien.bonnet@unilim.fr, camille.garcia@ijm.fr, thibaut.leger@ijm.fr,
17 mariepauline.couquet@gmail.com, philippe.vignoles@unilim.fr, vmlgedeao@live.com,
18 joseph.ndungu@finddx.org, boudot.clotilde@gmail.com, sbisser@pasteur-cayenne.fr,
19 bertrand.courtioux@unilim.fr

20
21 *Corresponding author

22 E-mail : julien.bonnet@unilim.fr

23

24 **Abstract**

25 Human African trypanosomiasis (HAT) is a neglected tropical disease that is endemic in sub-
26 Saharan Africa. Control of the disease has been recently improved by better screening and
27 treatment strategies, and the disease is on the WHO list of possible elimination. However, some
28 physiopathological aspects of the disease transmission and progression remain unclear. We
29 propose a new proteomic approach to identify new targets and thus possible new biomarkers of
30 the disease. We also focused our attention on fluids classically associated with HAT (serum and
31 cerebrospinal fluid (CSF)) and on the more easily accessible biological fluids urine and saliva.

32 Liquid chromatography–tandem mass spectrometry (LC-MS/MS) established the proteomic
33 profile of patients with early and late stage disease. The serum, CSF, urine and saliva of 3
34 uninfected controls, 3 early stage patients and 4 late stage patients were analyzed.

35 Among proteins identified, in CSF, urine and saliva, respectively, 37, 8 and 24 proteins were
36 differentially expressed and showed particular interest with regards to their function. The most
37 promising proteins (Neogenin, Neuroserpin, secretogranin 2 in CSF; moesin in urine and
38 intelectin 2 in saliva) were quantified by enzyme-linked immunosorbent assay in a confirmatory
39 cohort of 14 uninfected controls, 23 patients with early stage disease and 43 patients with late
40 stage disease. The potential of two proteins, neuroserpin and moesin, with the latter present in
41 urine, were further characterized.

42 Our results showed the potential of proteomic analysis to discover new biomarkers and provide
43 the basis of the establishment of a new proteomic catalogue applied to HAT-infected subjects and
44 controls.

45

46 **Key words:** Sleeping sickness, biological fluids, proteomic

47 **Introduction**

48 Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic disease,
49 caused by subspecies of *Trypanosoma brucei*, that mainly affects poor and rural communities in
50 more than 20 sub-Saharan African countries [1]. HAT is one of 20 neglected tropical diseases
51 (NTDs) recognized by the World Health Organization (WHO) [2], and it is estimated that 55
52 million people live at risk of contracting HAT infection [3]. In the human population, *T. b.*
53 *gambiense* is responsible for more than 98% of HAT cases in central and western Africa, *T. b.*
54 *rhodesiense* is responsible of the remaining 2% of cases, which is prevalent in eastern and
55 southern Africa. However, since 2009, fewer than 10,000 cases have been reported each year [3]–
56 [5].

57 Trypanosomes are inoculated into human hosts by tsetse fly vectors; the trypanosomes then
58 multiply and spread into the blood and lymphatic system. *T. b. gambiense* causes a chronic form
59 of disease that develops over months to years in two stages. The first stage (S1), or
60 hemolympathic stage, is generally characterized by intermittent fever, lymphadenopathy,
61 hepatosplenomegaly and headaches [5]. These symptoms are discrete and nonspecific for HAT.
62 After a variable duration of time, trypanosomes cross the blood–brain barrier and reach the
63 central nervous system (CNS); this stage is called the second stage (S2) or nervous stage. S2 is
64 characterized by neurological signs and symptoms and usually leads to death if untreated [6], [7].
65 Currently, several tests adapted to the field are used to diagnose HAT, the card agglutination test
66 for trypanosomiasis (CATT) is still the most widely used screening test although single-format
67 rapid diagnostic tests have been recently validated [8]. When the screening test is positive, the
68 disease must be confirmed by demonstrating the presence of the parasite by microscopy. The
69 tests used include blood concentration techniques such as the capillary tube centrifugation (CTC)

70 and mini anion exchange centrifugation technique (mAECT) [9], [10] or examination of lymph
71 node aspirates when lymph nodes are swollen. Once diagnosis of the disease is established by
72 one or more of these tests, it is important to stage the disease to guide treatment regimen. The
73 staging criteria defined by the WHO are the absence of trypanosomes in the cerebrospinal fluid
74 (CSF), and fewer than 5 white blood cells (WBC)/ μL CSF for patients with S1 disease, and the
75 presence of trypanosomes in the CSF and/or more than 6 WBC/ μL CSF for patients with S2
76 disease. These staging criteria are not always easy to use in settings where the disease occurs;
77 microscopy is not a sensitive enough technique to reliably detect the parasite in the CSF, and the
78 CSF WBC count is not specific for HAT [11]. Without the right diagnosis, S1 disease may
79 progress to S2 disease, and patients may not get the correct treatment. Patients with S1 *T. b.*
80 *gambiense* HAT are treated with pentamidine. S2 patients require treatments that can cross the
81 blood–brain barrier. ~~Second-stage~~ *Trypanosoma b. gambiense* S2 infection can be treated with a
82 nifurtimox–eflornithine combination therapy (NECT), but this treatment is given by infusion
83 which is invasive and difficult to perform in some areas [12]. For *T. b. rhodesiense*, melarsoprol
84 is the only treatment available [3]. A new easy-to-use treatment, named Fexinidazole, is expected
85 to be available in 2018. However, this treatment, even if it appears to be active in both stages of
86 the disease, is proposed as an alternative to NECT, therefore for the treatment of S2. The use of
87 pentamidine to treat S1 remains the current course of action [13]. Even if we can hope for the
88 arrival of a molecule that will allow us to treat both stages of the disease, greatly facilitating the
89 diagnostic and therapeutic plan of patients, the determination of the stage of the disease is still
90 necessary at this time.

91

92 The composition of the proteome of different biological fluids change with disease progression
93 and may lead to the generation of biomarkers that could be used in diagnosing and staging of the
94 disease [14]. Currently, proteome mapping is experiencing substantial growth owing to very
95 high-resolution techniques such as liquid chromatography–tandem mass spectrometry (LC-
96 MS/MS). Tandem mass spectrometry analysis allows a large proteome screen compared with
97 more specific techniques such as enzyme-linked immunosorbent assay (ELISA), immunoblotting
98 techniques and others that focus only on a single protein or small part of the proteome. The data
99 obtained with this technique, compared with the current human protein database, allow
100 identification and categorization of the proteins present in a biological sample with extensive
101 proteome coverage. Studies using LC-MS/MS have already discovered new biomarkers in many
102 diseases, such as Duchenne muscular dystrophy, amyotrophic lateral sclerosis, oral cavity
103 squamous cell carcinoma and breast cancer [15]–[18]. To enable the discovery of new
104 biomarkers from the proteome of biological fluids, it is important to characterize the entire
105 proteomes of both healthy and infected individuals. In this study, the serum, CSF, saliva and
106 urine proteomes obtained in patients with S1 and S2 *T. b. gambiense* HAT were compared with
107 uninfected controls. Using a high-resolution mass spectrometer coupled to a nano-ultra-
108 performance liquid chromatography (UPLC) system, several proteins with variable abundance
109 levels between the different groups were revealed by label-free protein quantification analysis.
110 The objective of this study was to characterize the proteome of serum, CSF, urine and saliva from
111 patients with *T. b. gambiense* HAT and to identify biological markers that could be used in
112 disease diagnosis and staging.

113 **Material and Methods**

114 **Subjects and sample collection**

115 The samples used in this study were collected during a prospective cohort study carried out
116 between 2009 and 2011 in three provinces in Angola: Bengo, Uíge and Kwanza Norte. The study
117 enrolled 247 Angolan subjects: 67 were classified as S1 patients, 161 as S2 patients, and 19 as
118 controls. All patients were designated HAT positive by CATT (with or without titration), and
119 trypanosomes demonstration by microscopy in the blood or in lymph node aspiration. Patients in
120 the cohort had *T. b. gambiense* HAT, and were staged before treatment. Patients with no
121 trypanosomes in the CSF and normal WBC counts (≤ 5 WBC/ μ L CSF) were classified as S1
122 patients. Patients with a WBC counts of more than 5 WBC/ μ L CSF and/or presence of
123 trypanosomes in the CSF were classified as S2 patients. Controls were subjects who had tested
124 positive for HAT by CATT but without parasite confirmation in blood, lymph node or CSF and
125 without development of the disease during the whole follow-up period. Every subject was
126 examined clinically and submitted to a questionnaire to document clinical and neurological
127 characteristics. Neurological data included an index of depression, measured with the Hamilton
128 rating scale [19], and the sleep and psychiatric disturbance using the Mini-International
129 neuropsychiatric interview [20]. Main co-infections were excluded in the field by microscopy for
130 common parasitic co-infections (blood smear for malaria, CTC for detection of filariasis,
131 examination of a urine sediment for schistosomiasis when urine was positive for blood).

132 Retrospectively, samples were tested for HIV and syphilis, and all positive samples were
133 excluded from the study.

134 For both controls and patients, samples of 5 mL of serum, 4 mL of CSF, 2 mL of urine and 2 mL
135 of saliva were stored in liquid nitrogen, transported to Limoges (France), in dry tanks and further

136 stored at -80°C. Samples used for this study were carefully selected among the cohort and
137 common co-infections were excluded.

138 **Ethics statement**

139 Ethical clearance was obtained from the Direccao National de Saude Publica, Ministerio da
140 Saude, Angola. Written informed consent was obtained from all participants and, for participants
141 below 18 years of age, from their parents or guardians, prior to enrolment. Any individual who
142 declined to participate was managed according to the standard procedures of the national HAT
143 control program.

144 **Study design**

145 Potential biomarkers were first screened in serum, CSF, urine and saliva on a small population of
146 controls and patients by mass spectrometry and, second, the most promising biomarkers were
147 then quantified on a larger cohort.

148 ***The screening cohort (n = 10)***

149 LC-MS/MS analysis was done on uninfected controls (n = 3), S1 patients (n = 3) and S2 patients
150 (n = 4). Only adult males were included to avoid variations of the proteome linked to the
151 expression of hormonal proteins.

152 ***Quantitative analysis of the validation cohort by ELISA (n = 80)***

153 Protein quantification was done on samples collected after inclusion for controls (n = 14), S1
154 patients (n = 23) and S2 patients (n = 43). All samples used for the LC-MS/MS analysis were
155 included for protein quantification.

156 Two analyses were done: the first to identify among the detected proteins those that differentiated
157 controls from patients with HAT (n = 66); the second to verify whether these proteins could

158 discriminate S1 from S2 patients. The most promising proteins that could differentiate S1 and S2
159 patients were also quantified at 12 months follow-up to verify their potential to be a marker of
160 cure.

161 **LC-MS/MS analysis**

162 *Sample preparation*

163 Serum, CSF, saliva and urine samples were used in this analysis. A preliminary step of depletion
164 has been carried out to reduce the quantity of predominant proteins (α 1-Acid Glycoprotein, α 1-
165 Antitrypsin, alpha 2-Macroglobulin, Albumin, Apolipoprotein A-I, Apolipoprotein A-II,
166 Fibrinogen, Haptoglobin, IgA, IgG, IgM, Transferrin) in these biological fluids. The dynamic
167 range of protein concentrations in different human fluids can be large. Without this step, the high
168 abundance of these predominant proteins would overwhelm the data obtained for the analysis of
169 low abundance proteins. Samples containing 10 μ g of protein, after depletion (Proteome purify
170 12 Human, R&D Systems®) and concentration (AMICON ULTRA, Merck Millipore®), were
171 adjusted to 120 μ L of the reaction mixture containing 4 M urea, 1.5 M thiourea and 50 mM tris-
172 HCl pH 8.3. Proteins were reduced with 10 mM dithiothreitol for 30 min and then alkylated with
173 55 mM iodoacetamide for 20 min. Alkylated proteins were first digested with 500 ng of
174 endopeptidase lys-C (Wako®) for 3 h at room temperature (RT). Then the mixture was diluted
175 with 3 volumes of MilliQ-water and treated with 500 ng of trypsin (Sequence Grade Trypsin,
176 Promega®) for 16 h at RT. Enzymatic activity was stopped by addition of formic acid to a final
177 concentration of 3%. Samples were stored at -20 °C until use. In the case of saliva, a preliminary
178 acetone (100%) precipitation step at -20 °C was carried out. The saliva and urine samples were
179 not depleted to avoid a loss of proteins as the sample volume was low (1.5mL).

180 *Sample analysis*

181 Peptide mixtures (10 corresponding to patients) were analyzed by a Q-Exactive Plus coupled to a
182 Nano-LC Proxeon 1000 equipped with an easy spray ion source (all from Thermo Scientific).
183 Peptides were separated by chromatography with the following parameters: Acclaim PepMap100
184 C18 pre-column (2 cm, 75 μm i.d., 3 μm , 100 \AA), Pepmap-RSLC Proxeon C18 column (50 cm,
185 75 μm i.d., 2 μm , 100 \AA), 300 nL/min flow rate, gradient from 95 % solvent A (water, 0.1%
186 formic acid) to 35% solvent B (100 % acetonitrile, 0.1% formic acid) over a period of 98
187 minutes, followed by a column regeneration for 23 min, giving a total run time of 2 hours.
188 Peptides were analyzed in the Orbitrap cell, in full ion scan mode, at a resolution of 70,000 (at
189 m/z 200), with a mass range of m/z 375–1500 and an AGC target of 3×10^6 . Fragments were
190 obtained by high collision-induced dissociation (HCD) activation with a collisional energy of
191 30%, and a quadrupole isolation window of 1.4 Da. MS/MS data were acquired in the Orbitrap
192 cell in a Top20 mode, at a resolution of 17,500, with an AGC target of 2×10^5 , with a dynamic
193 exclusion of 30 seconds. The most intense precursor ions were acquired first by MS/MS. Peptides
194 with unassigned charge states or monocharged were excluded from the MS/MS acquisition. The
195 maximum ion accumulation time was set to 50 ms for MS acquisition and 45 ms for MS/MS
196 acquisition.

197 ***Peptide and protein identification***

198 For the peptide and protein identification step, all MS and MS/MS data were processed with
199 Proteome Discoverer software (Thermo Scientific, version 2.1) and with Mascot search engine
200 (Matrix Science, version 5.1). The mass tolerance was set to 6 ppm for precursor ions and 0.02
201 Da for fragments. The maximum number of missed cleavages was limited to two for the trypsin
202 protease. The SwissProt database with the *Homo sapiens* and the *T. b. gambiense* taxonomies was
203 used for the MS/MS identification step. The following variable modifications (2 maximum per
204 peptide) were allowed: oxidation (M) and carbamidomethylation (C). Peptide identification in all

205 fluids analyzed were validated using a 1% FDR (false discovery rate) threshold calculated with
206 the Percolator algorithm [21].

207 *Peptide and protein abundance quantification and statistical validation*

208 Progenesis QI for Proteomics software (version 4.0, Waters) was used for the relative
209 quantification of the protein abundances by using co-detection to eliminate missing values. No
210 filters based on peptide by protein occurrences were applied for the protein quantification. The
211 relative quantitation of proteins according to the three groups (Control, S1 and S2 patients) was
212 performed using a between subject analysis and a Hi-3 method for which the three most abundant
213 peptides were used for protein quantification. Abundance variations of proteins with an ANOVA
214 *p*-value under 0.05 were further considered. The protein fold change makes it possible to show a
215 difference of this protein abundance according to the groups when it is greater than 2. The
216 potential biological role of each selected protein was verified and completed by a complete
217 bibliographic review to confirm its interest.

218 **Validation of protein abundance variations by ELISA**

219 *Selection of ELISA assays*

220 Human neuroserpin ELISA, BioVendor® (LOD-Limit of Detection: 0.03 ng/mL), human NEO1
221 ELISA Kit, Mybiosource® (LOD: 5.00 pg/mL) and human SCG2 ELISA Kit, Elabscience
222 Biotechnology® (LOD: 0.75 ng/mL) were selected to detect levels of neuroserpin, neogenin and
223 secretogranin 2 in CSF, respectively. The level of neuroserpin detection on diagnosis samples
224 allowed further detection at 12 months follow-up. Human moesin ELISA kit, Abbexa Ltd®
225 (LOD: 0.054 ng/mL) and human ITLN2 ELISA kit, Elabscience® (LOD: 3.75 ng/mL) were used
226 to detect levels of moesin in urine and levels of ITNL2 in saliva, respectively. For each ELISA

227 test, the protocol provided by the manufacturer was followed. Optical densities (OD) were
228 measured with a Multiskan go (Thermo Scientific®) spectrophotometer.

229 *Statistical analysis*

230 Using the data obtained by ELISA, cut offs and receiver operating characteristic (ROC) curves
231 were made to determine the best sensitivity/specificity ratio for each marker. The significance has
232 been evaluated using Kruskal–Wallis test and Fisher's exact test for testing the null of
233 independence. The level of agreement with cut offs found in the literature was estimated using
234 Cohen's kappa coefficient and generalized linear models were used to make logistic regressions.
235 Tests were performed using R Core Team [22]. The following packages were used: ROCR for
236 drawing curves [23] and PMCMR for pairwise comparisons of Kruskal–Wallis test [24].

237 .

238

239 **Results**

240 **Population characteristics**

241 Demographic, clinical and biological data are summarized in Table 1. All screening cohort
242 selected patients and controls were male. Biological, neurological and parasitological
243 examination showed that no controls suffered from sleep or neurological disorders, no
244 trypanosomes were found in their blood or CSF, and their average WBC count was 4.61
245 WBC/ μ L CSF. S1 patients had similar clinical characteristics to the control group but with
246 presence of trypanosomes in blood and an average of 1.33 WBC/ μ L CSF. S2 patients had
247 confirmed neurological signs and sleep disorders; their average WBC count was 195.79 WBC/ μ L
248 CSF.

249 The protein quantification cohort included 14 controls (sex ratio: 0.56), 23 S1 patients (sex ratio:
250 0.92) and 43 S2 patients (sex ratio: 0.54). Biological, neurological and parasitological
251 examination showed that no controls had trypanosomes in the blood or CSF. The CSF
252 examination of one of these controls revealed the presence of 8 WBC/ μ L, but no co-infection was
253 detected for this patient, and the neurological examination did not reveal any disorders. Among
254 the controls only 2 patients had sleep disorders. All S1 patients had trypanosomes in the blood
255 and a WBC count between 0 and 4 WBC/ μ L CSF. None of the S1 patients had trypanosomes in
256 the CSF, and the neurological examination showed that 6 patients had neurological disorders, and
257 10 had sleep disorders. All S2 patients had trypanosomes in the blood, and 23 out of 43 patients
258 had trypanosomes in the CSF. The WBC count of these patients ranged from 6 to 597 WBC/ μ L
259 CSF. Neurological examinations showed that 70% (30/43) of these patients had neurological
260 disorders, and 67% (29/43) had sleep disorders.

261 For the quantification of proteins in urine and saliva, samples were not available for all controls
262 and patients. For urine samples, the analysis was done on 13 controls, 21 S1 patients and 38 S2
263 patients. For saliva samples, the analysis was done on 13 controls, 22 S1 patients and 38 S2
264 patients.

265

266 **Global LC-MS/MS analysis**

267 Searching the LC-MS/MS data for semi-tryptic peptides in the protein database allows the
268 identification of any possible protein degradation of the samples caused by the method and
269 duration of freezing. There were no major differences between the samples of occurrences of
270 peptides derived from non-tryptic endogenous proteases. This analysis was carried out on the
271 screening cohort samples and showed that the biological samples of these patients had not been
272 degraded.

273 The samples were tested for the presence of peptides described in the *T. b. gambiense* protein
274 database; however, although parasite proteins were identified in each of the 4 biological fluids
275 tested, they were not studied further owing to a lack of validation of protein identification.
276 However, they are present in the database published in supplementary files.

277 Analysis of the total number of different proteins identified in serum, CSF, saliva and urine for
278 each group of individuals (controls, S1 patients and S2 patients) (Figure 1) showed that S2
279 patients had a decrease in the number of different proteins expressed in the CSF compared with
280 control and S1 patients. For saliva, the mean total number of different proteins identified in S2
281 patients (472 different proteins) was less than the total number of different proteins identified in
282 S1 patients (594 different proteins) and by the control group (627 different proteins). The total
283 number of proteins expressed in sera was similar in the different groups. For urine, the lowest
284 total number of proteins identified was found in the controls.

285 Figure 1: Distribution of the number of proteins identified in the serum, CSF, saliva and urine of
286 the screening cohort with respect to disease stage.

287 Captions: The total number of different proteins identified by LC-MS/MS analysis in serum,
288 cerebrospinal fluid (CSF), urine and saliva in boxplots ~~and a table~~. Boxplots show the maximum
289 and minimum number of proteins identified by LC-MS/MS, the means and quartiles for each
290 fluid analyzed. For serum, CSF and urine data there are 3 controls (C), 3 patients with stage 1
291 (S1) disease and 4 patients with Stage 2 (S2) disease. For saliva there are 2 controls, 3 patients
292 with S1 disease and 4 patients with S2 disease. The mean number of different proteins identified
293 by LC-MS/MS analysis in serum, cerebrospinal fluid (CSF), urine and saliva are available in
294 supplementary data.

295 **LC-MS/MS analysis and protein quantification in sera**

296 The proteomic analysis of the 10 screening cohort serum samples showed the presence of 269
297 proteins. The 10 best-scored proteins are presented in table 2. These data are heavily skewed
298 owing to the very high levels of some serum proteins, such as albumin and immunoglobulins,
299 despite the use of depletion protocols. This is highlighted by the presence of proteins with high
300 identification scores, which are normally depleted, in table 2. As such, any changes in protein
301 levels specific to HAT are not statistically pertinent.

302

303 **LC-MS/MS analysis and protein quantification in CSF**

304 The proteomic analysis of the screening cohort CSF samples showed the presence of 491
305 proteins. The relative abundances of these proteins were estimated by label-free quantification
306 with Progenesis QI software. Among these proteins, 159 were found differentially abundant
307 (ANOVA *p*-value lower than 0.05 and Fold Change higher than 2) between controls, S1 or S2
308 patients. After analysis of these 159 proteins on the basis of their statistical data (ANOVA *p*-
309 value and fold change), their differences attributable to disease stage, and their biological role, 37
310 proteins presented potential interest in HAT characterization (Table 3). Neogenin, secretogranin 2
311 and neuroserpin were chosen for protein quantification in CSF samples as their results showed
312 the best combination of our defined criteria. Briefly, the ANOVA *p*-value calculated for neogenin
313 is 3.82×10^{-5} , and the fold change is close to infinity; the average normalized abundance (ANA)
314 calculations showed an expression of this protein only in controls and S1 patients (2.72×10^4 and
315 2.17×10^4 , respectively) (Table 3). The ANOVA *p*-value calculated for secretogranin 2 is 5.45×10^{-5}
316 and the fold change is 11.27 (Table 3). More secretogranin 2 is found in the CSF of healthy
317 controls (ANA: 2.49×10^6) and S1 patients (ANA: 2.01×10^6) than in S2 patients (ANA: 2.21×10^5).

318 The most significant ANOVA result was obtained for neuroserpin at 2.61×10^{-8} , and the Fold
319 Change was close to infinity (Table 3). This protein is present in the CSF of healthy controls
320 (ANA: 2.5×10^4) and S1 patients (ANA: 2.32×10^4) but not in S2 patients.

~~321 Protein quantification by ELISA was performed for the 3 proteins meaningful results were not
322 obtained for neogenin and secretogranin 2. For neogenin, the amount was too low to be detected
323 by ELISA, and for secretogranin 2, similar concentrations were found for controls, S1 and S2
324 patients. Mean values obtained were 0.27 ng/mL, with a standard deviation of 0.003. It was thus
325 not possible to use secretogranin 2 as a possible marker of differentiation for patients or controls.~~

326 Protein quantification by ELISA was performed for the 3 proteins, but for neogenin an
327 secretogranin 2, the amount was too low to be detected by ELISA. It was therefore not possible to
328 use them as a possible marker of differentiation for patients or controls. Only the neuroserpin
329 ELISA results showed significant differences (Figure 2) and allowed statistical tests to be
330 performed for further analysis. There was no difference in neuroserpin CSF concentration
331 between the control and patients at inclusion when analyzed by the Kruskal–Wallis test; however,
332 neuroserpin levels were significantly different ($p < 0.05$) between S1 and S2 patients. ROC curve
333 analysis was used to determine the threshold level of neuroserpin for discriminating S2 patients
334 from S1 patients (area under the curve (AUC): 0.72). It was determined that a level of CSF
335 neuroserpin below 4.99 ng/mL was indicative of a patient having S2 disease (sensitivity: 0.94 and
336 specificity: 0.58). Logistic regression analysis showed that age and sex of individuals have no
337 effect on CSF neuroserpin concentration; however, there was a correlation between neuroserpin
338 concentration and presence of sleep disorders (odds ratio: 2.1×10^{-02} (CI: 1.0×10^{-3} ; 1.47×10^{-1}), $p <$
339 0.01) and neurological disorders (odds ratio: 6.3×10^{-2} (CI: 0.9×10^{-2} ; 2.32×10^{-1}), $p <$
340 0.001). Similarly, a link could be made between the presence of trypanosomes in the CSF and the
341 concentration of neuroserpin (odds ratio: 5.09×10^{-4} (CI: 1.93×10^{-4} ; 4.22×10^{-2}), $p <$ 0.001).

342 Figure 2: Changes in the neuroserpin concentration in CSF of controls and patients with stage 1
343 and stage 2 HAT at inclusion and after 12 months

344 Captions: Neuroserpin concentrations in the CSF for 14 healthy controls, 23 S1 patients and 43
345 S2 patients; the concentrations for 5/14 of the controls 16/23 of the S1 patients and 28/43 of the
346 S2 patients after 12 months of treatment are also shown.

347

348 Neuroserpin levels were then tested for association with sleep and neurological disorders and the
349 presence of trypanosomes in the CSF. The Kruskal–Wallis test revealed that CSF neuroserpin
350 could act as a marker for these disease-associated pathologies ($p < 0.05$). A ROC curve was used
351 to determine the threshold of 5.09 ng/mL, below which patients had sleep disorders (AUC: 0.79;
352 sensitivity: 0.72 and specificity: 0.67). The ROC curve analysis also allowed us to determine a
353 threshold of 4.97 ng/mL of CSF neuroserpin (AUC: 0.77), below which the patients had
354 neurological disorders (sensitivity: 0.9 and specificity: 0.59). The threshold of CSF neuroserpin
355 determined by ROC curve analysis for discriminating the presence of trypanosomes in the CSF
356 (AUC = 0.95) is 4.83 ng/mL, below which is indicative of CSF invasion by trypanosomes
357 (sensitivity: 0.98 and specificity: 0.91). The discriminating power of CSF neuroserpin was tested
358 against the parasitological examination of CSF (gold standard) with an agreement of 0.88
359 (Cohen's kappa coefficient), which is an excellent concordance.

360 At follow-up, at 12 months following treatment, the neuroserpin concentration was quantified in
361 the CSF in 5/14 of the controls, 16/23 of the S1 patients and 28/43 of the S2 patients. Kruskal–
362 Wallis analysis showed that there was no difference in neuroserpin levels between the 3 groups
363 after 12 months post-treatment, and the concentrations at 12 months were close to those found in
364 the control and S1 patients at inclusion. The mean neuroserpin concentration in the CSF in all the
365 groups is 5.13 ng/mL (Figure 2).

366

367 **LC-MS/MS analysis and protein quantification in urine**

368 The proteome analysis of urine samples showed the presence of 664 proteins, and 32 proteins
369 were differentially abundant (ANOVA p -value lower than 0.05 and Fold Change higher than 2)
370 between the control and the S1 or the S2 patients. From these 32 proteins, 8 were chosen as
371 interesting (Table 4). Moesin appeared to be the most promising protein for quantification by

372 ELISA at inclusion. The ANOVA p -value for moesin analysis was 9.38×10^{-3} and its fold change
373 was 47.11 (Table 4). Moesin is increased in S1 patients (ANA: 7.12×10^4) and S2 patients (ANA:
374 1.57×10^4) compared with the controls (ANA: 1511.77). Quantification of moesin at 12 months
375 follow-up was not possible owing to the low number of urine samples available.

376 The moesin ELISA was performed on samples from 59 patients from both S1 and S2 patients and
377 13 uninfected controls. The Kruskal–Wallis test revealed a significant difference in moesin levels
378 ($p < 0.05$) between controls and patients with HAT. The threshold for discriminating controls
379 from patients was determined with ROC curve analysis (AUC = 0.70). A level of moesin above
380 0.448 ng/mL (sensitivity: 0.64 and specificity: 0.61) in urine is indicative of HAT disease.
381 Further characterization of moesin levels between S1 ($n = 21$) and S2 patients ($n = 38$) compared
382 with uninfected controls ($n=13$) was performed. No statistical difference in moesin abundance
383 levels was observed between uninfected controls and S1 patients and no significant difference
384 was observed between S1 and S2 patients. However, when comparing the uninfected controls and
385 S2 patients, a significant difference in moesin levels was found ($p < 0.05$). ROC curve analysis
386 (AUC: 0.72) was used to determine a urine moesin threshold of 0.60 ng/mL (sensitivity: 0.63 and
387 specificity: 0.65) above which patients had S2 HAT. Using logistic regression, it was shown that
388 the moesin concentrations were not influenced by sex, age, presence of trypanosomes in CSF, or
389 sleep and neurological disorders.

390

391 **LC-MS/MS analysis and protein quantification in saliva**

392 The screening was carried out on the screening cohort but with only 2 controls (owing to an error
393 in tube labelling). The proteome screening of saliva allows the identification of 954 proteins.
394 Among these 954 proteins, 137 were found to be differentially abundant (ANOVA p -value lower
395 than 0.05 and fold change higher than 2) between the control and the S1 or the S2 patients, and

396 24 were chosen for their particular interest (Table 5). Among them intelectin 2 (ITLN2) was
397 chosen for quantification by ELISA. ITLN2 had an ANOVA of 1.23×10^{-4} and a Fold Change of
398 120.23 as determined by quantitative proteomics; ANA, determined by Progenesis QI software
399 analysis, showed lower ITLN2 concentration in the saliva of patients in both stages (S1 ANA:
400 258.69; S2 ANA: 350.60) than controls (ANA: 3.11×10^4).

401 Saliva ITLN2 concentrations measured by ELISA of controls ($n = 13$) and those of patients ($n =$
402 60) were compared with the Kruskal–Wallis test. There was no significant difference between the
403 two populations ($p = 0.40$). Saliva ITLN2 concentrations were then compared between S1
404 patients ($n = 22$), the S2 patients ($n = 38$) and uninfected controls ($n = 13$) using the Kruskal–
405 Wallis test. There was no significant difference in ITLN2 levels between controls, S1 and S2
406 patients ($p = 0.06$). Therefore, it was not possible to determine a threshold for this protein (AUC
407 $= 0.59$).

408 **Discussion**

409 This is, to our knowledge, the first simultaneous proteomic characterization of 4 biological fluids
410 (serum, CSF, saliva and urine) from the same HAT patients. The proteome screening analysis by
411 LC-MS/MS has revealed 69 proteins (37 proteins in CSF, 8 proteins in saliva and 24 proteins in
412 urine) that could be interesting for diagnosis or staging of the disease. The potential of 5 proteins
413 (3 proteins in CSF, 1 protein in urine and 1 protein in saliva) were further verified as biomarkers
414 in diagnosis or staging. These assays are a preliminary step in the identification of the entire
415 proteome of HAT patients.

416 The semi-tryptic peptide analysis of the database showed that the method and the freezing
417 duration of our samples did not alter the proteome quality. However, very few proteins or
418 degraded fragments from the parasite were identified owing to poor Mascot scores. This may be
419 due to the low quantity of parasitic proteins relative to the amount of human proteins and/or to
420 limitations or absence of *T. b. gambiense* proteins in the existing database. This needs to be
421 further investigated, which is why our study was focused on the human proteome and the
422 detection of biomarkers for S2 patients and not on parasite proteins.

423 In sera, the label-free quantification did not identify any protein of notable interest (ANOVA: <
424 0.05 and Fold Change: > 2). The quantification by LC-MS/MS of an exhaustive set of proteins in
425 serum is difficult; this is partly due to the complexity of the serum, which contains a large
426 number of different proteins with an extremely large range of expression [25], [26]. In this case,
427 despite the depletion step carried out, the presence of a large quantity of proteins (mainly
428 albumins and globulins) impedes quantification of other proteins as shown in other studies [27].

429 In the CSF, the protein composition showed a clear decrease in the diversity and number of
430 identified proteins in patients with S2 disease. This result is surprising but can be explained by

431 two physiopathological mechanisms that may act together. The first is trypanosome-induced
432 immunosuppression [28]–[30], which is a marked weakening of the humoral response owing to
433 massive B cell death [31], [32]. Furthermore, it has been described that the release of
434 trypanosome suppression immunomodulating factor by the parasite triggers the development of
435 suppressive M1 macrophages [33] and blocks T cell proliferation [34]. This immunosuppression
436 could explain the decrease in the number of proteins found in the CSF of the patients with S2
437 disease because the disappearance of the immune cells implies a decrease of the proteins related
438 to them. The second explanation is a leakage or resorption of nervous system proteins owing to
439 the permeabilization of the blood–brain barrier [35], [36]. The loss of nervous system proteins
440 and increase in plasma-associated protein, such as complement system proteins, albumin,
441 transthyretin and apolipoproteins has been described by others in CNS infections altering the
442 blood–brain barrier [37]–[39] and was corroborated in the CSF analysis of our study.

443
444 In CSF, the analysis allowed the identification of 491 proteins, of which many had been
445 previously associated with HAT, such as vascular cell adhesion protein 1 (VCAM1) [40], [41]
446 and osteopontin (SPP1) [42]. The study focused on 37 proteins that were differentially expressed
447 between the uninfected controls, S1 and S2 patients, and 3 proteins — namely neogenin,
448 secretogranin 2 and neuroserpin — were chosen for further analysis by ELISA [43]–[50].
449 Neogenin is a protein associated with the nervous system, and it has already been proposed as a
450 biomarker in other pathologies [45], [50]. In the brain, neogenin is a receptor for many proteins,
451 including repulsive guidance molecule (RGM) family members, which is involved in axon
452 guidance, apoptosis and neuronal differentiation [46], [50]. The use of the RGMa–neogenin
453 signaling pathway as a therapeutic target to overcome inflammatory and neurodegenerative
454 diseases has already been proposed [50]. Secretogranin 2 is a soluble member of the granin

455 protein family, which are widely distributed in neuroendocrine and nervous system tissues.
456 ~~Granins are stored in large dense core vesicles within neurons; secretogranin 2 can also be~~
457 ~~detected in glial cells [43]. Secretogranin 2 has numerous functions, including neurite outgrowth~~
458 ~~and chemoattractive effects on monocytes, eosinophils and endothelial cells [43]. In 2013,~~
459 ~~Jakobsson *et al* proposed secretogranin 2 as a CSF marker for severe forms of bipolar disorder.~~
460 ~~Patients with bipolar disorder have defects in the regulatory secretory pathway; one of the altered~~
461 ~~proteins is secretogranin 2 [48], and reduction is linked to severe forms. Reduced levels of~~
462 ~~secretogranin 2 and secretogranin 3 were observed in serum and CSF samples of patients with~~
463 ~~multiple sclerosis [45], [47], [49]. In our HAT sample collection, neogenin and secretogranin 2~~
464 ~~were highlighted by LC MS/MS analysis; however, the ELISA assay used seemed unable to~~
465 ~~detect these proteins, which may be due to the detection limit of the commercial ELISA test~~
466 ~~being too high for the samples in this study. In our HAT sample collection, neogenin and~~
467 ~~secretogranin 2 were highlighted by LC-MS/MS analysis; however, our patients had neogenin~~
468 ~~and secretogranin 2 concentrations under the ELISA assay limit of detection.~~
469 Finally, among the tested proteins, only neuroserpin allowed the discrimination of disease stage
470 with a decrease in neuroserpin concentrations with disease progression. This is the first study
471 showing a link between neuroserpin and HAT. Neuroserpin is a protein belonging to the serine
472 protease inhibitor superfamily, which is expressed throughout the nervous system but more
473 particularly at the latter stages of the development of neuronal cells [44], [51], [52]. Neuroserpin
474 inhibits the activation of tissue plasminogen and has an essential role in axogenesis, synaptic
475 plasticity [53], memory and brain development [54], [55]. Neuroserpin is linked to familial
476 encephalopathy with neuroserpin inclusion bodies (FENIB) [56]. This dementia is due to point
477 mutations favoring the polymerization of neuroserpin and its retention in endoplasmic reticulum
478 of neurons [56]–[58]. This protein is also associated with Alzheimer disease, but its role is not yet

479 clearly identified [59]–[61]. To date, we have no knowledge of work studying the relationship
480 between neuroserpin and HAT. The decrease in late stage disease could be due to the fact that
481 neuroserpin is predominantly expressed in the neurons of the hippocampus, caudate and cerebral
482 cortex [62], [63]. The hippocampus and the caudate are close to the choroid plexus, which is
483 described in the literature as the first route of entry of the parasite into the brain owing to the
484 absence of the blood–brain barrier at this location [64]–[66]. It is probable that these regions are
485 the first to be affected by the presence of the trypanosome. ELISA quantification allowed us to
486 determine a cut-off point for neuroserpin, below which HAT patients may be considered to be in
487 S2 (4.99 ng/mL; sensitivity: 0.94 and specificity: 0.58) at diagnosis. Patients with a neuroserpin
488 concentration greater than 4.99 ng/mL are considered in S1 of the disease. Levels had returned to
489 normal at 12 months follow up, suggesting that the decrease is directly linked to the presence of
490 the parasite or the elicited immune reaction. It was also possible to determine that the onset of
491 sleep disorders was associated with a CSF neuroserpin concentration of less than 5.09 ng/mL.
492 This last cut-off could explain how some patients with S1 disease present symptoms of sleep
493 disorders [67], [68]. Similarly, the presence of trypanosome in the CSF was correlated with a
494 CSF neuroserpin concentration of less than 4.84 ng/mL. Each of these cut-offs correlate with
495 classical stage markers, indicating that neuroserpin may be considered as a good additional or
496 unique marker if its concentration is easy to quantify.

497
498 The identification of biomarkers in alternative fluids such as urine and saliva is extremely
499 interesting for field screenings or use in resource-limited countries. Access to these fluids is
500 noninvasive, and collection can be done by non-qualified people, or they can even can be used
501 for self-diagnosis [69], [70]. Currently, saliva is a source of biomarkers for neurological diseases
502 [71], HIV [72], diabetes [73]–[75] and cancer [76], [77]; urine is used for the diagnosis of

503 osteoclastogenesis [78], urological cancer [79], and proteins in the urine have been identified as
504 potential biomarkers for breast cancer [80], Alzheimer disease [81] and Parkinson disease [82].
505 In urine, proteins linked to infectious processes have been highlighted. Moesin was the most
506 interesting according to our identification criteria. This protein belongs to the family of ezrin–
507 radixin–moesin (ERM) proteins, and it is involved in angiogenesis. In fact, the phosphorylation
508 of moesin allows the mediation of endothelial angiogenesis [83]. This protein also participates in
509 the connection between the cytoskeleton and the plasma membrane of human cells. This property
510 allows this protein to limit infection with herpes simplex virus 1 [84]. It has been shown to have a
511 role in invasion of *Trypanosoma cruzi* amastigotes into human cells [85]. Moesin is also involved
512 in the regulation, proliferation and adhesion of human lymphoid cells [86]. A mutation of this
513 protein leads to primary immunodeficiency [87]. The involvement of moesin in kidney lesions
514 was established by Chen *et al* [88]; however, its role is not clear. The ERM complex intervenes in
515 the cellular dynamics by taking part in the mobility of cancer cells described in oral cancers and
516 carcinomas [89], [90]. In our study, moesin levels were elevated in urine samples from S1 and S2
517 patients compared with uninfected controls. This result was corroborated by the ELISA
518 quantification. ELISA quantification shows that there is a significant difference between moesin
519 concentrations in uninfected controls compared with patients. Furthermore, a difference in
520 moesin concentration was observed between the uninfected controls and S2 patients, which could
521 make it possible to discriminate stage when the presence of the parasite is established in the
522 blood. It was subsequently impossible to carry out the analysis at 12-months follow-up as not
523 enough samples were available.

524
525 In saliva, 24 potential interesting proteins were identified that are differentially expressed, and
526 ITLN2 was chosen as a potential candidate biomarker owing to its physiopathological

527 background. However, ITLN2 levels detected by ELISA could not discriminate controls from
528 patients, nor S1 from S2 patients ($p = 0.06$). It does not appear aberrant to find this protein in an
529 inflammatory pathology such as HAT [91], [92]. The intelectin families, and particularly ITLN2,
530 are proteins expressed principally in the small intestine. ITLN2 is involved in host–pathogen
531 interactions [93] and iron metabolism [94] and allergic inflammation [91]. Studies are currently
532 determining any potential antimicrobial and anti-parasitic activity of ITLN2 [91], [92], [95].
533 However, the presence of ITLN2 and its role in saliva remains unexplained. The quantification of
534 this protein on a larger sample could make it possible to identify the pathophysiological role of
535 this protein in HAT.

536

537 There can be some bias in saliva and urine analysis. In case of saliva, intra- and inter-individual
538 composition variations can be influenced by many parameters, such as salivary flow, sex, age, the
539 subject's emotional state, season, nycthemeral rhythm and medication [96]. In the same way,
540 external elements to the salivary system, such as nasal and bronchial secretions, the gingival
541 fluid, epithelial cells, microbial flora and food debris, can modify its composition [97], [98]. It is
542 recommended to perform the saliva collection before brushing the teeth and at least 30 minutes
543 after any ingestion of food [99]. For urine, the time of sample collection was not calibrated
544 (between 7 am and 1 pm) and thus may lead to variations in urine composition and concentration.
545 In this study, these variations could not all be controlled and may constitute a bias.

546 One weakness of this study is the number of patients that were selected for the screening by LC-
547 MS/MS analysis. Indeed, for practical reasons 10 patients were selected among the 247 included
548 in the cohort for the analysis of screening, for which there is homogeneous data (age, sex and no
549 co-infection detected). Despite the low number of patient samples analyzed by LC-MS/MS, the
550 patient sampling in each group (controls, S1 and S2) is statistically homogenous. Another

551 possible criticism is the lack of uniformity in the sampling times, which is especially important in
552 the case of urine and saliva.

553 **Conclusion**

554 In conclusion, our work allowed the characterization of a large number of proteins presenting an
555 interest in the understanding of HAT pathophysiology and diagnosis. The high sensitivity of new
556 technologies such as LC-MS/MS allow the discovery of new candidate disease marker and open
557 the path to other more accessible biological fluids like urine or saliva. Our work identified two
558 potential new markers, neuroserpin and moesin, the latter of which is found in urine, which could
559 simplify diagnostic strategies in the field.

560 **Graphical abstract**

561 ~~Human samples of sera, CSF, saliva and urine from screening cohort were prepared for LC-~~
562 ~~MS/MS analysis.~~ Human African trypanosomiasis samples (sera, CSF, saliva and urine) from a
563 screening cohort were prepared for characterization of disease biomarkers by LC-MS/MS
564 analysis. Bottom-up identification of proteins allows to categorize 269 proteins in the serum, 491
565 proteins in the CSF, 954 proteins in the saliva and 664 proteins in the urine. Among these
566 proteins identified, 37 proteins in the CSF, 24 proteins in the saliva and 8 proteins in the urine
567 were differentially abundant between the control, the S1 or the S2 patients and were of interest
568 for HAT diagnosis. Among these proteins, 5 were assayed by ELISA in the protein quantification
569 cohort: neogenin, secretogranin 2 and neuroserpin in the CSF; intelectin 2 in the saliva and
570 moesin in the urine.

571 *For saliva screening cohort: controls (n = 2), S1 patients (n = 3) and S2 patients (n = 4).

572

573 **Supplementary data**

574 Table represents the average number of different proteins identified by LC-MS/MS analysis in
575 serum, cerebrospinal fluid (CSF), urine and saliva. For serum, CSF and urine data there are 3
576 controls (C), 3 patients with stage 1 (S1) disease and 4 patients with Stage 2 (S2) disease. For
577 saliva there are 2 controls, 3 patients with S1 disease and 4 patients with S2 disease.

578

579 **Highlights**

580

581 LC-MS/MS analysis allow the discovery of new candidate disease markers for HAT.
582 Neuroserpin and moesin are two potential new markers that could simplify diagnostics.
583 CSF protein composition showed a clear decrease of identified proteins in S2 patients.
584 Easily accessible biological fluids, like urine, could be used for HAT diagnosis.

585

586 **Ethics approval and consent to participate**

587 Ethical clearance was obtained from the Direccao National de Saude Publica, Ministerio da
588 Saude, Angola. The authorization for automated processing of personal data relating to the study
589 was obtained from the Comité Consultatif sur le Traitement de l'Information en matière de
590 Recherche dans le domaine de la Santé (CCTIRS) (N° 08.228bis)

591

592 **Consent for publication**

593 Written informed consent was obtained from all participants and, for participants below 18 years
594 of age, from their parents or guardians, prior to enrolment. Any individual who declined to
595 participate was managed according to the standard procedures of the national HAT control
596 program.

597

598 **Availability of data and material**

599 The complete data sets are available in the PRIDE partner repository [100] under the
600 identification number : PXD007842 as .raw files, Proteome Discoverer 2.1 .pdResult file,
601 associated pep.xml and xlsx files, and label-free report generated by Progenesis QI.

602 **Username:** reviewer10851@ebi.ac.uk

603 **Password:** NL6d28RK

604 **Supporting Information Legends:** Identification and relative quantification of all peptides/proteins
605 from the proteomics experiments and according to the different experimental conditions are
606 publicly available via ProteomeXchange and the PRIDE partner repository under the
607 identification number: PXD007842 as.raw files, Proteome Discoverer 2.1. pdResult file,
608 associated pep.xml and xlsx files, and label-free report generated by Progenesis QI.

609

610 **Competing interests**

611 The authors declare that they have no competing interests

612

613 **Funding**

614 This work was supported by the Foundation for Innovative and New Diagnostic (FIND 2008)
615 (<https://www.finddx.org>) and Conseil Regional de la Nouvelle Aquitaine and INSERM.

616

617 **Acknowledgements**

618 The manuscript has been revised for the English by an independent scientific language editing
619 service.

620 References

- 621 [1] P. Büscher, G. Cecchi, V. Jamonneau, and G. Priotto. Human African trypanosomiasis.
622 The Lancet. 2017; 390:2397-2409.
- 623 [2] Strategic and Technical Advisory Group on NTDs (STAG). 10th meeting of the Strategic
624 and Technical Advisory Group for Neglected Tropical Diseases. WHO, Geneva,
625 Switzerland. 2017.
- 626 [3] WHO. Report of the second WHO stakeholders meeting on gambiense human African
627 trypanosomiasis elimination. 2016.
- 628 [4] P. P. Simarro, A. Diarra, J. A. Ruiz Postigo, J. R. Franco, and J. G. Jannin. The Human
629 African Trypanosomiasis Control and Surveillance Programme of the World Health
630 Organization 2000–2009: The Way Forward. PLoS Negl. Trop. Dis. 2011; 5 (2): e1007.
- 631 [5] J. R. Franco, P. P. Simarro, A. Diarra, and J. G. Jannin. Epidemiology of human African
632 trypanosomiasis. Clin. Epidemiol. 2014; 6: 257-275.
- 633 [6] R. Brun, J. Blum, F. Chappuis, and C. Burri. Human African trypanosomiasis. The Lancet.
634 2010; 375 (9709): 148-159.
- 635 [7] S. Mogk, A. Meiwes, S. Shtopel, U. Schraermeyer, M. Lazarus, B. Kubata et al. Cyclical
636 Appearance of African Trypanosomes in the Cerebrospinal Fluid: New Insights in How
637 Trypanosomes Enter the CNS. PLoS ONE. 2014; 9 (3): e91372.
- 638 [8] S. Bisser, C. Lumbala, E. Nguertoum, V. Kande, L. Flaveau, G. Vatunga et al. Sensitivity
639 and Specificity of a Prototype Rapid Diagnostic Test for the Detection of *Trypanosoma*
640 *brucei gambiense* Infection: A Multi-centric Prospective Study. PLoS Negl. Trop. Dis.
641 2016; 10 (4): e0004608.
- 642 [9] P. Lutumba, J. Robays, C. Miaka, V. Kande, D. Mumba, P. Büsher et al. Validity, cost and
643 feasibility of the mAECT and CTC confirmation tests after diagnosis of African of
644 sleeping sickness. Trop. Med. Int. Health TM IH. 2006; 11 (4): 470-478.
- 645 [10] P. Büscher, D. Mumba Ngoyi, J. Kaboré, V. Lejon, J. Robays, V. Jamonneau et al.
646 Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and
647 Modified Single Centrifugation (MSC) for Sleeping Sickness Diagnosis and Staging. PLoS
648 Negl. Trop. Dis. 2009; 3 (11): e471.
- 649 [11] D. Mumba Ngoyi, J. Menten, P. P. Pyana, P. Büscher, and V. Lejon. Stage determination
650 in sleeping sickness: comparison of two cell counting and two parasite detection
651 techniques. Trop. Med. Int. Health TM IH. 2013; 18 (6): 778-782.
- 652 [12] A. H. Fairlamb. Chemotherapy of human African trypanosomiasis: current and future
653 prospects. Trends Parasitol. 2003; 19 (11): 488-494.
- 654 [13] V. K. B. K. Mesu, W.M. Kalonji, C. Bardonneau, O. V. Mordt, S. Blesson, F. Simon et al.
655 Oral fexinidazole for late-stage African *Trypanosoma brucei gambiense* trypanosomiasis: a
656 pivotal multicentre, randomised, non-inferiority trial. The Lancet. 2018; 391 (10116): 144-
657 154.
- 658 [14] Z. Meng and T. D. Veenstra. Proteomic analysis of serum, plasma, and lymph for the
659 identification of biomarkers. Proteomics Clin. Appl. 2007; 1 (8): 747-757.
- 660 [15] J. Rouillon, A. Zocevic, T. Leger, C. Garcia, J.M. Camadro, B. Ubb et al. Proteomics
661 profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular
662 dystrophy. Neuromuscul. Disord. NMD. 2014; 24 (7): 563-573.

- 663 [16] J. Beretov, V. C. Wasinger, E. K. A. Millar, P. Schwartz, P. H. Graham, and Y. Li.
664 Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a
665 Label-Free LC-MS/MS Approach. *PloS One*. 2015; 10 (11): e0141876.
- 666 [17] C.-C. Wu, H.-W. Chu, C.-W. Hsu, K.-P. Chang, and H.-P. Liu. Saliva proteome profiling
667 reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma.
668 *Proteomics*. 2015; 15 (19): 3394-3404.
- 669 [18] M. A. Collins, J. An, B. L. Hood, T. P. Conrads, and R. P. Bowser. Label-Free LC-MS/MS
670 Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and
671 Candidate Biomarkers for Amyotrophic Lateral Sclerosis. *J. Proteome Res*. 2015; 14 (11):
672 4486-4501.
- 673 [19] M. Hamilton. A rate scale for depression. *J. Neurol. Neurosurg. Psychiatry*. 1960; 23: 56-
674 62.
- 675 [20] D. V. Sheehan, Y. Lecrubier, K. H. Sheehan, P. Amorim, J. Janavs, E. Weillers et al. The
676 Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation
677 of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J. Clin.*
678 *Psychiatry*. 1998;59 Suppl 20:22-33-57.
- 679 [21] M. Brosch, L. Yu, T. Hubbard, and J. Choudhary. Accurate and sensitive peptide
680 identification with Mascot Percolator. *J. Proteome Res*. 2009; 8 (6): 3176-3181.
- 681 [22] R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
682 Austria: R Foundation for Statistical Computing, 2016.
- 683 [23] T. Sing, O. Sander, N. Beerenwinkel, and T. Lengauer. ROCR: Visualizing the
684 Performance of Scoring Classifiers. 2015.
- 685 [24] T. Pohlert. PNCMR: Calculate Pairwise Multiple Comparisons of Mean Rank Sums. 2016.
- 686 [25] L. Anderson. Candidate-based proteomics in the search for biomarkers of cardiovascular
687 disease. *J. Physiol*. 2005; 563 (1): 23-60.
- 688 [26] S. Hu, J. A. Loo, and D. T. Wong. Human body fluid proteome analysis. *Proteomics*. 2006;
689 6 (23): 6326-6353.
- 690 [27] N. L. Anderson and N. G. Anderson. The Human Plasma Proteome History, Character, and
691 Diagnostic Prospects. *Mol. Cell. Proteomics*. 2002; 1 (11): 845-867.
- 692 [28] G. Low and A. Castellani. Report of the Sleeping Sickness Commission. *Proc R Soc*
693 *London*. London; 1903.
- 694 [29] K. A. Taylor. Immune responses of cattle to African trypanosomes: protective or
695 pathogenic? *Int. J. Parasitol*. 1998; 28 (2): 219-240.
- 696 [30] T. N. Baral. Immunobiology of African trypanosomes: need of alternative interventions. *J.*
697 *Biomed. Biotechnol*. 2010; 2010: 389153.
- 698 [31] M. Radwanska, P. Guirnalda, C. D. Trez, B. Ryffel, S. Black, and S. Magez.
699 Trypanosomiasis-Induced B Cell Apoptosis Results in Loss of Protective Anti-Parasite
700 Antibody Responses and Abolishment of Vaccine-Induced Memory Responses. *PLOS*
701 *Pathog*. 2008; 4 (5): e1000078.
- 702 [32] V. Bockstal, P. Guirnalda, G. Caljon, R. Goenka, J. C. Telfer, D. frenkel et al. *T. brucei*
703 Infection Reduces B Lymphopoiesis in Bone Marrow and Truncates Compensatory
704 Splenic Lymphopoiesis through Transitional B-Cell Apoptosis. *PLOS Pathog*. 2011; 7 (6):
705 e1002089.
- 706 [33] J. Gómez-Rodríguez, B. Stijlemans, G. De Muylder, H. Korf, L. Brys, M. Berberof et al.
707 Identification of a parasitic immunomodulatory protein triggering the development of
708 suppressive M1 macrophages during African trypanosomiasis. *J. Infect. Dis*. 2009; 200
709 (12): 1849-1860.

- 710 [34] B. Stijlemans, G. Caljon, J. Van Den Abbeele, J. A. Van Ginderachter, S. Magez, and C.
711 De Trez. Immune Evasion Strategies of *Trypanosoma brucei* within the Mammalian Host:
712 Progression to Pathogenicity. *Front. Immunol.* 2016; 7: 233.
- 713 [35] D. J. Grab, O. Nikolskaia, Y. V. Kim, J. D. Lonsdale-Ecces, S. Ito, T. Hara et al. African
714 trypanosome interactions with an in vitro model of the human blood-brain barrier. *J.*
715 *Parasitol.* 2004; 90 (5): 970-979.
- 716 [36] D. J. Grab, J. C. Garcia-Garcia, O. Nikolskaia, Y. V. Kim, A. Brown, C. A. Pardo et al.
717 Protease Activated Receptor Signaling Is Required for African Trypanosome Traversal of
718 Human Brain Microvascular Endothelial Cells. *PLoS Negl. Trop. Dis.* 2009; 3 (7): e479.
- 719 [37] R. Jurado and H. K. Walker. Cerebrospinal Fluid. In: *Clinical Methods: The History,*
720 *Physical, and Laboratory Examinations*, 3rd ed., H. K. Walker, W. D. Hall, and J. W.
721 Hurst, Eds. Boston: Butterworths; 1990.
- 722 [38] H. Reiber and J. B. Peter. Cerebrospinal fluid analysis: disease-related data patterns and
723 evaluation programs. *J. Neurol. Sci.* 2001; 184 (2): 101-122.
- 724 [39] B. J. Blyth, A. farhavar, C. Gee, B. Hawthorn, H. He, A. Nayak et al. Validation of Serum
725 Markers for Blood-Brain Barrier Disruption in Traumatic Brain Injury. *J. Neurotrauma.*
726 2009; 26 (9): 1497-1507.
- 727 [40] C. Mulenga, J. D. Mhlanga, K. Kristensson, and B. Robertson. *Trypanosoma brucei brucei*
728 crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic
729 disease model. *Neuropathol. Appl. Neurobiol.* 2001; 27 (1): 77-85.
- 730 [41] A. Hainard, N. Tiberti, X. Robin, D. M. Ngoyi, E. Matovu, J. C. Enyaru et al. Matrix
731 metalloproteinase-9 and intercellular adhesion molecule 1 are powerful staging markers for
732 human African trypanosomiasis. *Trop. Med. Int. Health.* 2011; 16 (1): 119-126.
- 733 [42] N. Tiberti, A Hainard, V. Lejon, X. Robin, D. M. Ngoyi, N. Truck et al. Discovery and
734 verification of osteopontin and Beta-2-microglobulin as promising markers for staging
735 human African trypanosomiasis. *Mol. Cell. Proteomics MCP.* 2010; 9 (12): 2783-2795.
- 736 [43] R. Fischer-Colbrie, R. Kirchmair, A. Schobert, C. Olenik, D. K. Meyer, and H. Winkler.
737 Secretogranin II Is Synthesized and Secreted in Astrocyte Cultures. *J. Neurochem.* 1993;
738 60 (6): 2312-2314.
- 739 [44] G. A. Hastings, T. A. Coleman, C. C. Haudenschild, S. Stefansson, E. P. Smith, R.
740 Barthlow et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is
741 localized primarily in neurons. Implications for the regulation of motor learning and
742 neuronal survival. *J. Biol. Chem.* 1997; 272 (52): 33062-33067.
- 743 [45] N. Mattsson, U. Rüetschi, V. N. Podust, M. Stridsberg, S. Li, O. Andersen. Cerebrospinal
744 fluid concentrations of peptides derived from chromogranin B and secretogranin II are
745 decreased in multiple sclerosis. *J. Neurochem.* 2007; 103 (5): 1932-1939.
- 746 [46] N. H. Wilson and B. Key. Neogenin: one receptor, many functions. *Int. J. Biochem. Cell*
747 *Biol.* 2007; 39 (5): 874-878.
- 748 [47] F. Li, X. Tian, Y. Zhou, L. Zhu, B. Wang, M. Ding and H. Pang. Dysregulated expression
749 of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis. *J.*
750 *Neurosci. Res.* 2012; 90 (12): 2237-2246.
- 751 [48] J. Jakobsson, M. Stridsberg, H. Zetterberg, K. Blennow, C. J. Ekman, A. G. Johansson et
752 al. Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar
753 disorder. *J. Psychiatry Neurosci. JPN.* 2013; 38 (4): E21-E26.
- 754 [49] I. Begcevic, D. Brinc, A. P. Drabovich, I. Batruch, and E. P. Diamandis. Identification of
755 brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and
756 mining of the Human Protein Atlas. *Clin. Proteomics.* 2016; 13: 11.

- 757 [50] Y. Fujita and T. Yamashita. The roles of RGMa-neogenin signaling in inflammation and
758 angiogenesis. *Inflamm. Regen.* 2017; 37: 6.
- 759 [51] S. R. Krueger, G. P. Ghisu, P. Cenelli, T. P. Gschwend, T. Osterwalder, D. P. Wolfer and
760 P. Sonderegger. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in
761 the developing and adult nervous system of the mouse. *J. Neurosci. Off. J. Soc. Neurosci.*
762 1997; 17 (23): 8984-8996.
- 763 [52] T. W. Lee, V. W. K. Tsang, E. J. Loef, and N. P. Birch. Physiological and pathological
764 functions of neuroserpin: Regulation of cellular responses through multiple mechanisms.
765 *Semin. Cell Dev. Biol.* 2017; 62: 152-159.
- 766 [53] S. Caccia, S. Ricagno, and M. Bolognesi. Molecular bases of neuroserpin function and
767 pathology. *Biomol. Concepts.* 2010; 1 (2): 117-130.
- 768 [54] T. Osterwalder, J. Contartese, E. T. Stoeckli, T. B. Kuhn, and P. Sonderegger.
769 Neuroserpin, an axonally secreted serine protease inhibitor. *EMBO J.* 1996; 15 (12): 2944-
770 2953.
- 771 [55] T. W. Lee, V. W. K. Tsang, and N. P. Birch. Physiological and pathological roles of tissue
772 plasminogen activator and its inhibitor neuroserpin in the nervous system. *Front. Cell.*
773 *Neurosci.* 2015; 9: 396.
- 774 [56] R. L. Davis, A. E. Shrimpton, P. D. Holohan, C. Bradshaw, D. Feiglin, G. H. Collins et al.
775 Familial dementia caused by polymerization of mutant neuroserpin. *Nature.* 1999; 401
776 (6751): 376-379.
- 777 [57] E. Miranda, I. Macleod, M. J. Davies, J. Perez, K. Römisch, D. C. Crowther and D. A.
778 Lomas. The intracellular accumulation of polymeric neuroserpin explains the severity of
779 the dementia FENIB. *Hum. Mol. Genet.* 2008; 17 (11): 1527-1539.
- 780 [58] R. Noto, M. G. Santangelo, S. Ricagno, M. R. Mangione, M. Levantino, M. Pezzulo et al.
781 The Tempered Polymerization of Human Neuroserpin. *PLoS ONE.* 2012; 7 (3): e32444.
- 782 [59] K. J. Kinghorn, D. C. Crowther, L. K. Sharp, C. Nerelius, R. L. Davis, H. T. Chang et al.
783 Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in
784 Alzheimer disease. *J. Biol. Chem.* 2006; 281 (39): 29268-29277.
- 785 [60] A. Chiou, P. Hägglöf, A. Orte, A. Y. Chen, P. D. Dunne, D. Belorgy et al. Probing
786 neuroserpin polymerization and interaction with amyloid-beta peptides using single
787 molecule fluorescence. *Biophys. J.* 2009; 97 (8): 2306-2315.
- 788 [61] B. Subhadra, K. Schaller, and N. W. Seeds. Neuroserpin up-regulation in the Alzheimer's
789 disease brain is associated with elevated thyroid hormone receptor- β 1 and HuD expression.
790 *Neurochem. Int.* 2013; 63 (5): 476-481.
- 791 [62] T. Teesalu, A. Kulla, A. Simisker, V. Sirèn, D. A. Lawrence, T. Asser and A. Vaeri. Tissue
792 plasminogen activator and neuroserpin are widely expressed in the human central nervous
793 system. *Thromb. Haemost.* 2004; 92 (2): 358-368.
- 794 [63] M. Uhlén, L. Fagerberg, B. M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu et al.
795 Proteomics. Tissue-based map of the human proteome. *Science.* 2015; 347 (6220):
796 1260419.
- 797 [64] M. Schultzberg, M. Ambatsis, E. B. Samuelsson, K. Kristensson, and N. van Meirvenne.
798 Spread of *Trypanosoma brucei* to the nervous system: early attack on circumventricular
799 organs and sensory ganglia. *J. Neurosci. Res.* 1988; 21 (1): 56-61.
- 800 [65] O. V. Nikolskaia, Y. V. Kim, O. Kovbasnjuk, K. J. Kim, and D. J. Grab. Entry of
801 *Trypanosoma brucei gambiense* into microvascular endothelial cells of the human blood-
802 brain barrier. *Int. J. Parasitol.* 2006; 36 (5): 513-519.

- 803 [66] O. V. Nikolskaia, A. P. de A Lima, Y. V. Kim, J. D. Lonsdale-Ecces, T. Fukuma, J.
804 Scharfstein and D. J. Grab. Blood-brain barrier traversal by African trypanosomes requires
805 calcium signaling induced by parasite cysteine protease. *J. Clin. Invest.* 2006; 116 (10):
806 2739-2747.
- 807 [67] E. Bertrand, F. Serie, I. Kone, J. Rive, L. Compaore, L. Sentilhes and J. Philippe.
808 Symptomatologie générale de la trypanosomiase humaine africaine au moment du
809 dépistage. *Méd. Afr. noire*, 1973; 20 (4): 303-314.
- 810 [68] K. Urech, A. Neumayr, and J. Blum. Sleeping Sickness in Travelers - Do They Really
811 Sleep? *PLoS Negl. Trop. Dis.* 2011; 5 (11): e1358.
- 812 [69] D. Malamud. Saliva as a diagnostic fluid. *Dent. Clin. North Am.* 2011; 55 (1): 159-178.
- 813 [70] L. A. S. Nunes, S. Mussavira, and O. S. Bindhu. Clinical and diagnostic utility of saliva as
814 a non-invasive diagnostic fluid: a systematic review. *Biochem. Medica.* 2015; 25 (2):
815 177-192.
- 816 [71] M. S. M. Al-Nimer, S. F. Mshatat, and H. I. Abdulla. Saliva α -Synuclein and A High
817 Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of
818 Parkinson's Disease. *North Am. J. Med. Sci.* 2014; 6 (12): 633-637.
- 819 [72] K. Fransen, T. Vermoesen, G. Beelaert, J. Menten, V. Hutse, K. Wouters et al. Using
820 conventional HIV tests on oral fluid. *J. Virol. Methods.* 2013; 194 (1-2): 46-51.
- 821 [73] A. J. Yoon, B. Cheng, E. Philipone, R. Turner, and I. B. Lamster. Inflammatory
822 biomarkers in saliva: assessing the strength of association of diabetes mellitus and
823 periodontal status with the oral inflammatory burden. *J. Clin. Periodontol.* 2012, 39 (5):
824 434-440.
- 825 [74] M. B. Border, S. Schwartz, J. Carlson, C. F. Dibble, H. Kohlfarber, S. Offenbacher et al.
826 Exploring salivary proteomes in edentulous patients with type 2 diabetes. *Mol. Biosyst.*
827 2012; 8 (4): 1304-1310.
- 828 [75] B. Zalewska-Szajda, S. Dariusz Szajda, N. Waszkiewicz, S. Chojnowska, E. Goscik, U.
829 Lebkowska et al. Activity of N-acetyl- β -D-hexosaminidase in the saliva of children with
830 type 1 diabetes. *Postepy Hig. Med. Doswiadczalnej Online.* 2013; 67: 996-999.
- 831 [76] J. W. Jenzano, N. F. Courts, D. A. Timko, and R. L. Lundblad. Levels of glandular
832 kallikrein in whole saliva obtained from patients with solid tumors remote from the oral
833 cavity. *J. Dent. Res.* 1986; 65 (1): 67-70.
- 834 [77] C. Streckfus, L. Bigler, M. Tucci, and J. T. Thigpen. A preliminary study of CA15-3, c-
835 erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women
836 with breast carcinoma. *Cancer Invest.* 2000; 18 (2): 101-109.
- 837 [78] S. P. Robins. Collagen crosslinks in metabolic bone disease. *Acta Orthop. Scand. Suppl.*
838 1995; 266: 171-175.
- 839 [79] H. Mlcochova, R. Hezova, M. Stanik, and O. Slaby. Urine microRNAs as potential
840 noninvasive biomarkers in urologic cancers. *Urol. Oncol.* 2014; 32 (1): 41.e1-9.
- 841 [80] V. P. Shichkin, A. D. Lon, L. G. Yuginova, Y. A. Grinevich, O. B. Belova, N. M.
842 Berezhnaya et al. TNF receptor p55 and IL-8(72) and IL-8(77) isoforms: blood and urine
843 levels in breast cancer patients. *J. Immunotoxicol.* 2009; 6 (4): 235-242.
- 844 [81] H. Ghanbari, K. Ghanbari, I. Beheshti, M. Munzar, A. Vasauskas, and P. Averback.
845 Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. *J. Clin. Lab.*
846 *Anal.* 1998; 12 (5): 285-288.
- 847 [82] J. Connolly, A. Siderowf, C. M. Clark, D. Mu, and D. Pratico. F2 isoprostane levels in
848 plasma and urine do not support increased lipid peroxidation in cognitively impaired

- 849 Parkinson disease patients. *Cogn. Behav. Neurol. Off. J. Soc. Behav. Cogn. Neurol.* 2008;
850 21 (2): 83-86.
- 851 [83] Q. Wang, A. Fan, Y. Yuan, L. Chen, X. Guo, X. Huang and G. Huang. Role of Moesin in
852 Advanced Glycation End Products-Induced Angiogenesis of Human Umbilical Vein
853 Endothelial Cells. *Sci. Rep.* 2016; 6: 22749.
- 854 [84] M. S. Henning, P. Stiedl, D. S. Barry, R. Mcahon, S. G. Morham, D. Walsh and M. H.
855 Naghavi. PDZD8 is a novel moesin-interacting cytoskeletal regulatory protein that
856 suppresses infection by herpes simplex virus type 1. *Virology.* 2011; 415 (2): 114-121.
- 857 [85] E. R. Ferreira, A. Bonfim-Melo, E. M. Cordero, R. A. Mortara. ERM Proteins play distinct
858 roles in cell invasion by extracellular amastigotes of *Trypanosoma cruzi*. *Front Microbiol.*
859 2017; 8: 2230.
- 860 [86] D. Pore and N. Gupta. Ezrin-Radixin-Moesin family proteins in the regulation of B cell
861 immune response. *Crit. Rev. Immunol.* 2015; 35 (1): 15-31.
- 862 [87] C. Lagresle-Peyrou, S. Luce, F. Ouchani, T. S. Soheili, H. Sadek, M. Chouteau et al. X-
863 linked primary immunodeficiency associated with hemizygous mutations in the moesin
864 (MSN) gene. *J. Allergy Clin. Immunol.* 2016; 138 (6): 1681-1689.
- 865 [88] Y. X. Chen, W. Chang, W. M. Wang, X. L. Yu, Y. M. Wang, M. J. Zhang and N. Chen.
866 Role of Moesin in Renal Fibrosis. *PLOS ONE.* 2014, 9 (11): e112936.
- 867 [89] T. Kinoshita, N. Nohata, M. Fuse, T. Hanazawa, N. Kkkawa, L. Fujimura et al. Tumor
868 suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell
869 proliferation and invasion in head and neck squamous cell carcinoma. *Biochem. Biophys.*
870 *Res. Commun.* 2012; 418 (2): 378-383.
- 871 [90] Y. Li, C.-X. Zhou, and Y. Gao. Moesin regulates the motility of oral cancer cells via MT1-
872 MMP and E-cadherin/p120-catenin adhesion complex. *Oral Oncol.* 2015; 51 (10): 935-
873 943.
- 874 [91] R. S. Peebles. The intelectins: a new link between the immune response to parasitic
875 infections and allergic inflammation? *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 2010; 298
876 (3): 288-289.
- 877 [92] D. A. Wesener, K. Wangkanont, R. McBride, X. Song, M. B. Kraft, H. L. Hodges et al.
878 Recognition of Microbial Glycans by Human Intelectin. *Nat. Struct. Mol. Biol.* 2015; 22
879 (8): 603-610.
- 880 [93] J. K. Lee, J. Schnee, M. Pang, M. Wolfert, L. G. Baum, K. W. Moremen and M. Pierce.
881 Human homologs of the *Xenopus* oocyte cortical granule lectin XL35. *Glycobiology.*
882 2001; 11 (1): 65-73.
- 883 [94] J. Yan, L. Xu, Y. Zhang, C. Zhang, C. Zhang, F. Zhao and L. Feng. Comparative genomic
884 and phylogenetic analyses of the intelectin gene family: implications for their origin and
885 evolution. *Dev. Comp. Immunol.* 2013; 41 (2): 189-199.
- 886 [95] A. D. Pemberton, P. A. Knight, J. Gamble, W. H. Coledge, J. K. Lee, M. Pierce and H. R.
887 Miller. Innate BALB/c enteric epithelial responses to *Trichinella spiralis*: inducible
888 expression of a novel goblet cell lectin, intelectin-2, and its natural deletion in C57BL/10
889 mice. *J. Immunol. Baltim. Md 1950.* 2004; 173 (3): 1894-1901.
- 890 [96] R. Vitorino, M. J. Lobo, A. J. Ferrer-Correira, J. R. Dubin, K. B. Tomer, D. P. M.
891 Domigues et al. Identification of human whole saliva protein components using
892 proteomics. *Proteomics.* 2004; 4 (4): 1109-1115.
- 893 [97] E. Kaufman and I. B. Lamster. The diagnostic applications of saliva-a review. *Crit. Rev.*
894 *Oral Biol. Med. Off. Publ. Am. Assoc. Oral Biol.* 2002; 13 (2): 197-212.

- 895 [98] D. Esser, G. Alvarez-Llamas, M. P. de Vries, D. Weening, R. J. Vonk, and H. Roelofsen.
896 Sample Stability and Protein Composition of Saliva: Implications for Its Use as a
897 Diagnostic Fluid. *Biomark. Insights*. 2008; 3: 25-27.
- 898 [99] M. Gröschl. Données actuelles sur l'analyse hormonale salivaire. *Ann. Biol. Clin.* 2009; 67
899 (5): 493-504.
- 900 [100] J. A. Vizcaíno, A. Csordas, N. del-Toro, J. A. Dienes, J. Griss, I. Lavidas et al. 2016
901 update of the PRIDE database and its related tools. *Nucleic Acids Res.* 2016; 44 (D1): 447-
902 456.
- 903

904

905 Table 1: Characteristics of the screening and protein quantification cohort

Screening cohort		Control	S1	S2
n		3	3	4
Sex-ratio (M/F)		3/0	3/0	4/0
Age (SD)		36.67 (27.15)	43.33 (21.13)	31.25 (18.14)
Neurological disorders		0	0	4
Sleep disorders		0	0	4
CSF WBC/ μ L (SD)		4.61 (3.05)	1.33 (0.58)	195.79 (147.44)
Trypanosome per μ L blood		0	3	4
Trypanosome per μ L CSF		0	0	4
Protein quantification cohort		Control	S1	S2
n *		14	23	43
Sex ratio (M/F)		5/9	11/12	15/28
Age	Mean (SD)	38 (20.14)	39.09 (14.17)	34.55 (12.93)
	Min	12	15	14
	Max	70	58	58
Neurological disorders		0	6	30
Sleep disorders		2	10	29
CSF WBC/ μ L (SD)		2.64 (1.90)	1.34 (0.93)	137.82 (165.73)
CSF WBC/ μ L	Min	0	0	6
	Max	8	4	597
Trypanosome per μ L blood		0	23	43
Trypanosome per μ L CSF		0	0	23

906
907
908 This table represents the epidemiological and biological data of 3 controls, 3 patients with stage 1
909 (S1) disease and 4 patients with stage 2 (S2) disease who constituted the screening cohort, as well
910 as the 14 controls, the 23 patients with S1 disease and the 43 patients with S2 disease enrolled in
911 protein quantification cohort. For urine and saliva analysis, some samples were not present in the
912 protein quantification cohort. *For urine (n = 72): 13 Controls, 21 S1 and 38 S2. For saliva (n =
913 73): 13 controls, 22 S1 and 38 S2.

914

915 Table 2: Top-10 best scored proteins identified in serum

Accession	Description	Score	ANOVA	Max Fold Change	Average normalized abundances Control	S1	S2
CO3_HUMAN	Complement C3	8016.88	0.82	1.31	1.91e+007	1.74e+007	1.46e+007
A2MG_HUMAN	Alpha-2-macroglobulin	5874.13	0.94	1.37	1.52e+007	1.67e+007	1.22e+007
VTDB_HUMAN	Vitamin D-binding protein	5127.27	0.87	1.11	9.21e+006	8.29e+006	8.67e+006
APOB_HUMAN	Apolipoprotein B-100	4819.10	0.35	2.68	2.89e+006	1.08e+006	1.08e+006
TRFE_HUMAN	Serotransferrin	4375.11	0.67	1.54	8.19e+006	1.26e+007	1.18e+007
CERU_HUMAN	Ceruloplasmin	4249.73	0.18	1.47	3.09e+007	2.30e+007	2.10e+007
HPT_HUMAN	Haptoglobin	3150.25	0.36	4.37	9.20e+006	1.34e+007	4.02e+007
A1AT_HUMAN	Alpha-1-antitrypsin	3085.22	0.63	1.22	3.80e+007	4.45e+007	3.64e+007
IGHM_HUMAN	Ig mu chain C region	2899.80	0.89	2.05	4.60e+007	3.58e+007	2.25e+007
IGKC_HUMAN	Ig kappa chain C region	2880.99	0.63	2.20	8.53e+007	7.25e+007	3.88e+007
IGHG1_HUMAN	Ig gamma-1 chain C region	2813.11	0.33	3.20	1.29e+007	4.14e+007	1.72e+007

916

917 S1: stage 1 disease; S2: stage 2 disease. Score: mascot protein score

918

919 Table 3: Most notable proteins in the CSF with altered abundance levels between control, S1 and
 920 S2 patients (classified by the increase in ANOVA *p*-value)

921

Accession	Description	Score	ANOVA	Max Fold Change	Average normalized abundances		
					Control	S1	S2
NEUS_HUMAN	Neuroserpin *	33.73	2.61e-008	Infinity	2.50e+004	2.32e+004	0.00
MCH_HUMAN	Pro MCH	18.23	2.53e-006	51.23	2.67e+004	2.31e+004	520.50
VG_F_HUMAN	Neurosecretory protein VGF	768.70	6.20e-006	17.49	1.46e+006	1.59e+006	9.10e+004
NDRG2_HUMAN	Protein NDRG2	26.38	9.85e-006	Infinity	3.65e+004	2.53e+004	0.00
NEO1_HUMAN	Neogenin *	27.68	3.82e-005	Infinity	2.72e+004	2.17e+004	0.00
PTPRS_HUMAN	Receptor type tyrosine protein phosphatase S	28.48	4.39e-005	Infinity	2.31e+004	1.55e+004	0.00
SCG2_HUMAN	Secretogranin 2 *	732.53	5.45e-005	11.27	2.49e+006	2.01e+006	2.21e+005
NCAM2_HUMAN	Neural cell adhesion molecule 2	123.80	2.49e-004	12.57	1.50e+005	1.43e+005	1.19e+004
AT1B1_HUMAN	Sodium/potassium transporting ATPase subunit beta 1	37.94	2.62e-004	6864.45	1361.14	2311.93	0.34
DHPR_HUMAN	Dihydropteridine reductase	112.47	3.39e-004	212.16	2.41e+004	2.52e+004	118.73
NFASC_HUMAN	Neurofascin	106.58	3.98e-004	19.75	4.44e+004	4.74e+004	2400.82
SCG3_HUMAN	Secretogranin 3	1068.39	4.07e-004	9.94	1.20e+006	1.46e+006	1.47e+005
SCG1_HUMAN	Secretogranin 1	4373.28	4.41e-004	6.14	1.59e+007	1.30e+007	2.58e+006
PEBP4_HUMAN	Phosphatidylethanolamine binding protein 4	23.40	4.51e-004	151.57	3.44e+004	1.89e+004	227.04
PCDH9_HUMAN	Protocadherin 9	42.21	4.54e-004	473.46	6.07e+004	6.17e+004	130.22
TICN3_HUMAN	Testican 3	111.74	1.24e-003	5.13	3.32e+004	2.87e+004	6478.72
NRX3A_HUMAN	Neurexin 3	37.45	1.33e-003	745.63	4182.12	9806.72	13.15
PTMA_HUMAN	Prothymosin alpha	78.55	1.40e-003	38.11	1.07e+005	6.51e+004	2.48e+006
PENK_HUMAN	Proenkephalin A	268.45	2.12e-003	4.34	4.07e+006	3.54e+006	9.39e+005
COL12_HUMAN	Collectin 12	134.26	3.30e-003	7.21	1.18e+005	7.12e+004	1.64e+004
SPON1_HUMAN	Spondin 1	77.80	3.35e-003	11.26	8.09e+004	4.53e+004	7181.93
CNTN2_HUMAN	Contactin 2	347.42	3.99e-003	78.73	6.75e+004	6.28e+004	857.46
TICN2_HUMAN	Testican 2	119.88	6.92e-003	9.75	5.79e+004	3.79e+004	5938.73
NCAM1_HUMAN	Neural cell adhesion molecule 1	709.91	8.60e-003	4.76	4.33e+005	3.25e+005	9.09e+004
CSTN1_HUMAN	Calsyntenin 1	293.93	9.35e-003	28.52	1.17e+005	1.24e+005	4346.68
CNTN1_HUMAN	Contactin 1	469.45	0.01	5.46	2.21e+005	1.60e+005	4.04e+004
CAD13_HUMAN	Cadherin 13	144.25	0.01	386.59	3.18e+004	4.65e+004	120.35
TIMP2_HUMAN	Metalloproteinase inhibitor 2	135.16	0.01	7.69	2.31e+005	1.47e+005	3.01e+004
L1CAM_HUMAN	Neural cell adhesion molecule L1	67.55	0.01	8.76	1.97e+004	1.95e+004	2254.34
TETN_HUMAN	Tetranectin	473.62	0.02	6.41	2.20e+005	2.53e+005	3.95e+004
OMGP_HUMAN	Oligodendrocyte myelin glycoprotein	296.85	0.02	3.60	3.26e+005	2.25e+005	9.03e+004
NEUM_HUMAN	Neuromodulin	129.92	0.02	2.67	1.58e+005	2.67e+005	9.99e+004
CBLN4_HUMAN	Cerebellin 4	24.53	0.02	2214.50	5630.78	4124.35	2.54
ECM1_HUMAN	Extracellular matrix protein 1	136.66	0.03	2.25	1.08e+006	1.16e+006	5.15e+005
PEBP1_HUMAN	Phosphatidylethanolamine binding protein 1	268.07	0.03	12.41	1.54e+005	1.94e+005	1.56e+004
TICN1_HUMAN	Testican 1	124.56	0.05	11.39	5.19e+004	5.17e+004	4556.89
MIF_HUMAN	Macrophage migration inhibitory factor	56.43	0.05	13.45	1.82e+004	2.73e+004	2031.17

922

923 All shown proteins passed thresholds of a fold change ≥ 2 and a *p*-value ≤ 0.05 . Score: mascot
 924 protein score. * Protein quantified by ELISA. S1: stage 1 disease; S2: stage 2 disease.

925

926 Table 4: Most notable proteins in the urine with altered levels between control, S1 and S2
 927 patients (classified by increase in ANOVA *p*-value)

	Description	Score	ANOVA	Fold Change	Average normalized abundances		
					Control	S1	S2
P51688	N-sulphoglucosamine sulphohydrolase	89.58	1.51e-004	Infinity	0.00	5.23e+004	1856.39
P16870	Carboxypeptidase E	23.90	1.61e-004	Infinity	0.00	2.06e+004	8488.37
P25774	Cathepsin S	151.85	5.80e-003	371.97	37.12	1.38e+004	621.63
P26038	Moesin *	319.43	9.38e-003	47.11	1511.77	7.12e+004	1.57e+004
P59190	Ras-related protein Rab-15	47.97	0.02	Infinity	0.00	1.74e+005	2088.10
P29622	Kallistatin	120.72	0.02	170.86	5936.72	4.28e+004	250.56
Q9H8L6	Multimerin 2	52.32	0.05	Infinity	0.00	8618.93	4.37e+004
P02766	Transthyretin	78.07	0.05	17.94	1.36e+004	1.42e+005	2.44e+005

928

929

930 All shown proteins passed thresholds of a fold change ≥ 2 and a *p*-value ≤ 0.05 . Score: mascot
 931 protein score. * Protein quantified by ELISA. S1: stage 1 disease; S2: stage 2 disease.

932

933 Table 5: Most notable proteins in the saliva with altered levels between control, S1 and S2

934 patients (classified by increase in ANOVA *p*-value)

935

Accession	Description	Score	ANOVA	Fold Change	Average normalized abundances		
					Control	S1	S2
P19878	Neutrophil cytosol factor 2	26.41	1.21e-005	Infinity	0.00	1207.94	8375.66
Q8WWU7	Intelectin 2 *	44.75	1.23e-004	120.23	3.11e+004	258.69	350.60
Q15643	Thyroid receptor-interacting protein 11	25.42	3.24e-004	Infinity	0.00	0.00	1.06e+005
P22392	Nucleoside diphosphate kinase B	36.48	1.87e-003	7.52	2.34e+004	4.61e+004	1.76e+005
Q04446	1,4-alpha-glucan-branching enzyme	40.31	0.01	28.76	515.25	7843.70	1.48e+004
P35241	Radixin	357.98	0.02	2.48	3.30e+005	3.79e+005	8.19e+005
P27348	14-3-3 protein theta	106.60	0.02	11.21	2444.76	1.19e+004	2.74e+004
Q04323	UBX domain-containing protein 1	101.23	0.02	408.77	27.88	5286.01	1.14e+004
P49913	Cathelicidin antimicrobial peptide	93.06	0.02	13.27	1.99e+004	3.28e+004	2.65e+005
O00602	Ficolin-1	84.63	0.02	43.65	620.60	1512.69	2.71e+004
Q9BQ10	Allograft inflammatory factor 1-like	41.75	0.02	Infinity	0.00	914.27	7081.79
P02753	Retinol-binding protein 4	24.27	0.02	3.59	2.92e+004	3.97e+004	1.05e+005
O60437	Periplakin	353.95	0.02	16.22	6164.29	1.30e+004	1.00e+005
Q9HC84	Mucin-5B	2457.44	0.03	11.30	2.98e+007	2.64e+006	5.98e+006
P05120	Plasminogen activator inhibitor 2	255.32	0.03	25.13	2266.87	3.00e+004	5.70e+004
P62136	Serine/threonine-protein phosphatase PP1-alpha catalytic subunit	130.27	0.03	23.02	1150.30	1.80e+004	2.65e+004
Q15631	Translin	49.17	0.03	20.39	722.18	2713.99	1.47e+004
P51888	Prolargin	22.23	0.03	17.73	3887.41	2.59e+004	6.89e+004
Q13813	Spectrin alpha chain, non-erythrocytic 1	257.23	0.04	11.90	2035.25	4051.54	2.42e+004
P99999	Cytochrome c	231.53	0.04	4.55	2.80e+004	4.21e+004	1.27e+005
P04632	Calpain small subunit 1	220.74	0.04	5.69	9299.74	2.29e+004	5.29e+004
P31997	Carcinoembryonic antigen-related cell adhesion molecule 8	60.26	0.04	26.63	3450.76	1.15e+004	9.19e+004
P30153	Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform	52.04	0.04	6.29	1660.25	6513.70	1.04e+004
Q15907	Ras-related protein Rab-11B	43.85	0.04	6.84	4755.71	2.47e+004	3.25e+004


936

937 All shown proteins passed thresholds of a fold change ≥ 2 and a *p*-value ≤ 0.05 . Score: mascot


938 protein score. * Protein quantified by ELISA, S1: stage 1 disease; S2: stage 2 disease.

939


Serum




CSF




Saliva



Urine





Screening cohort

Controls (n = 3), S1 patients (n = 3) and S2 patients (n = 4)

Serum



CSF




Saliva*



Urine



Proteome



Sample preparation & Enzymatic digestion

Peptides



Liquid Chromatography


MS/MS

Q Exactive plus® mass spectrometer

Identified protein

Serum	CSF	Saliva	Urine
269 proteins	491 proteins	954 proteins	664 proteins

Proteins identification



Protein quantification cohort

Controls (n = 14), S1 patients (n = 23) and S2 patients (n = 43)

	CSF	Saliva	Urine
proteins differentially abundant between groups	159 proteins	137 proteins	32 proteins
Proteins of interest	37 proteins	24 proteins	8 proteins
Protein dosed by ELISA	Neogenin Secretogranin 2 Neuroserpin	Intelectin 2	Moesin